+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

This research investigates the safety and tolerability of three different dose schedules of budoprutug, a humanized monoclonal antibody targeting CD19, in adults with primary membranous nephropathy PMN who test positive for anti-PLA2R antibodies and continue to have proteinuria despite optimized RAAS inhibitor treatment. The Phase 2, open-label, multicenter study aims to assess how this drug affects the immune system and kidney function in this condition. Participants will receive budoprutug intravenously on four specific days Day 1, Day 15, Day 169, and Day 183. The study includes three sequential groups, each receiving a different dose level of budoprutug. After dosing, participants will be followed for a total of 48 weeks to monitor safety and drug effects, with extended follow-up as needed to observe the recovery of B cells. During the study, participants will undergo assessments including blood tests to monitor B cell counts, anti-PLA2R antibody levels, kidney function eGFR, proteinuria, and urine albumin-to-creatinine ratio. Researchers will track any adverse events throughout the 48 weeks and evaluate the drugs pharmacokinetics. The total study participation lasts up to 48 weeks, with additional follow-up if necessary to ensure safety and recovery monitoring.

Age: 18Years - 75YearsAll GendersPhase 2
38 locations